HomeBUSINESS
BUSINESS

Durvalumab Improves PFS in Japanese NSCLC Patients
(Oct.17.2017)

AstraZeneca’s PD-L1 inhibitor durvalumab showed improvement in progression-free survival (PFS) in Japanese patients with locally-advanced unresectable non-small cell lung cancer (NSCLC), the company’s Japan unit said on October 16 ...
(LOG IN FOR FULL STORY)

News Calendar